Everything below concerns HPLC-UV. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Cellular thermal shift assay (CETSA) and proteome integral solubility alteration (PISA)-based proteomics are widely used in drug discovery as label-free, mass spectrometry–compatible methods for quantifying cellular target engagement (confirming that a drug binds its intended target), deconvoluting drug targets (identifying the protein target of compounds with unknown targets), and profiling off-target interactions at the proteome scale. CETSA measures drug-induced changes in protein thermal stability in intact cells or tissues and, when combined with proteomics, enables the unbiased identification and ranking of on- and off-targets, as well as supporting phenotypic hit mechanism-of-action studies. PISA extends thermal-shift principles by integrating protein solubility changes across a temperature gradient, substantially increasing throughput and enabling multiplexed analysis of multiple compounds, concentrations, or time points. This approach facilitates high-content target deconvolution and comparative mechanism-of-action profiling, including applications in low-input or automated workflows.
=== Mitochondria === The presence of progerin also leads to the accumulation of dysfunctional mitochondria within the cell. These mitochondria are characterized by a swollen morphology, caused by a condensation of mtDNA and TFAM into the mitochondria, which is driven by a severe mitochondrial dysfunction (low mitochondrial membrane potential, low ATP production, low respiration capacity and high ROS production). Therefore, contributing substantially to the senescence phenotype. Although the explanation for this defective-mitochondria accumulation in progeria is yet to be elucidated, it has been proposed that low PGC1-α expression (important for mitochondrial biogenesis, maintenance and function) along with low LAMP2 protein level and lysosome number (both important for mitophagy: the degradation of defective mitochondria pathway), could be implicated.
=== Astrochemistry === Several GC–MS systems have left earth. Two were brought to Mars by the Viking program. Venera 11 and 12 and Pioneer Venus analysed the atmosphere of Venus with GC–MS. The Huygens probe of the Cassini–Huygens mission landed one GC–MS on Saturn's largest moon, Titan. The MSL Curiosity rover's Sample analysis at Mars (SAM) instrument contains both a gas chromatograph and quadrupole mass spectrometer that can be used in tandem as a GC–MS. The material in the comet 67P/Churyumov–Gerasimenko was analysed by the Rosetta mission with a chiral GC–MS in 2014.
Results suggest that triptans, ditans, and gepants are all associated with reduced pain at 2 hours, with triptans being the most successful. Gepants were the least likely to cause adverse events, with some triptans having a higher risk than gepants, and ditans having the highest risk among all treatments.
Sources: en.wikipedia.org
=== Aquaculture === Methylene blue is used in aquaculture and by tropical fish hobbyists as a treatment for fungal infections. With the help of light, it is also effective against bacteria and viruses. It can also be effective in treating fish infected with the parasitic protozoa Ichthyophthirius multifiliis (ich), although a combination of malachite green and formaldehyde is far more effective against it. Methylene blue also works against nitrite poisoning as it treats the resulting methemoglobinemia. Like in humans, it also treats cyanide poisoning. Non-professional sources also claim that it works for ammonia poisoning, but there is little medical literature to back this up. It is usually used to protect newly laid fish eggs from being infected by fungus. This is useful when the hobbyist wants to artificially hatch the fish eggs. For poisoning, injury (prevention of infection), or sickness, methylene blue is given as a "medicated bath" for the fish. Methylene blue is not without side effects to fish.
Flexible linkers may consist of many small glycine residues, giving them the ability curl into a dynamic, adaptable shape. Rigid linkers may be formed of large, cyclic proline residues, which can be helpful when highly specific spacing between domains must be maintained. In vivo cleavable linkers are unique in that they are designed to allow the release of one or more fused domains under certain reaction conditions, such as a specific pH gradient, or when coming in contact with another biomolecule in the cell.
== Applications == Since the early 20th century electron ionization has been one of the most popular ionization techniques because of the large number of applications it has. These applications can be broadly categorized by the method of sample insertion used. The gaseous and highly volatile liquid samples use a vacuum manifold, solids and less volatile liquids use a direct insertion probe, and complex mixtures use gas chromatography or liquid chromatography.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.